Cagrilintide Research Peptide

Peptora Research Peptide Library

Cagrilintide Research Peptide Overview

Cagrilintide Research Peptide is a long-acting, lipidated analogue of the pancreatic hormone amylin developed for research into amylin-receptor signalling, appetite regulation, satiety, energy intake and metabolic biology. Its clinical research program includes studies of cagrilintide alone and separate studies in which cagrilintide is co-administered with the GLP-1 analogue semaglutide.

Explore Research Materials Retatrutide Overview Tirzepatide Overview Testing & COAs

Peptide overview

What Is the Cagrilintide Research Peptide?

Cagrilintide is an engineered, long-acting analogue of amylin, also known as islet amyloid polypeptide. Natural amylin is produced by pancreatic beta cells and is co-secreted with insulin.

Amylin participates in physiological signalling related to satiety, food intake and gastric function. Cagrilintide was developed through structural modification of the amylin framework to improve stability and extend exposure compared with short-acting amylin-related compounds.

Cagrilintide Research Peptide at a Glance

Research class: long-acting amylin analogue.

Biological reference: pancreatic amylin / islet amyloid polypeptide.

Design: engineered and lipidated peptide analogue.

Primary research system: amylin-receptor signalling.

Research areas: satiety, appetite regulation, energy intake, body-weight regulation and metabolic biology.

Clinical research: investigated both as cagrilintide alone and in combination with semaglutide.

Amylin biology

Cagrilintide Research Peptide and Natural Amylin

Amylin is a peptide hormone released from pancreatic beta cells alongside insulin. Its biological role differs from that of GLP-1, GIP or glucagon even though these systems can intersect within metabolic research.

Research has linked amylin signalling with neural pathways involved in satiation and regulation of food intake. This makes the amylin system a distinct experimental target within metabolic research.

Pancreatic Origin

Natural amylin is produced by pancreatic beta cells and is co-secreted with insulin.

Amylin Receptor Research

Cagrilintide was designed to reproduce and extend amylin-related receptor activity.

SAT

Satiety Research

Amylin-related signalling has been investigated in neural systems involved in satiation and food intake.

MET

Metabolic Research

The peptide has become part of broader research into body-weight regulation and metabolic physiology.

Molecular engineering

How Cagrilintide Was Designed as a Long-Acting Amylin Analogue

Natural human amylin presents significant pharmaceutical-development challenges, including a tendency to form amyloid fibrils. Earlier amylin analogues demonstrated that the pathway could be targeted, but short duration of exposure remained an important limitation.

Cagrilintide was developed through structure-activity research aimed at producing a stable, long-acting amylin analogue. Published medicinal-chemistry research describes it as a stable, lipidated long-acting amylin analogue.

Natural Amylin Pancreatic peptide hormone

→

Peptide Engineering Structural modifications

→

Lipidation Extended exposure design

→

Cagrilintide Long-acting amylin analogue

Research distinction: cagrilintide is an engineered amylin analogue. Findings involving cagrilintide should not automatically be treated as identical to findings involving natural human amylin or another amylin analogue.

Receptor biology

Amylin Receptor Signalling in Cagrilintide Research

Amylin receptor biology is more complex than a single standalone receptor protein. Functional amylin receptors arise from calcitonin-receptor complexes associated with receptor-activity-modifying proteins, commonly called RAMPs.

This receptor architecture is relevant when interpreting amylin-analogue research because the signalling system is distinct from GLP-1 receptor signalling.

Amylin Receptors

Cagrilintide belongs to a research class designed around amylin-receptor agonism.

Central Signalling

Amylin biology includes signalling in brain regions involved in satiation and regulation of food intake.

Food-Intake Research

Experimental and clinical programs have evaluated amylin analogues in relation to appetite and energy intake.

Distinct Pathway

Amylin-receptor signalling should be distinguished from GLP-1, GIP and glucagon receptor pathways.

Phase 2 research

Cagrilintide Research Peptide as a Standalone Compound

A multicentre phase 2 trial evaluated once-weekly cagrilintide in adults with overweight or obesity without diabetes. The randomized, double-blind study included multiple cagrilintide groups, placebo groups and an active comparator.

The trial demonstrated a dose-dependent pattern of body-weight change across cagrilintide groups during the study period and helped establish the compound's clinical research profile.

Phase 2 Research

Standalone Cagrilintide Clinical Research

The study was conducted at 57 sites across ten countries and enrolled adults without diabetes who had obesity or overweight with specified accompanying conditions.

Researchers evaluated several cagrilintide groups across the dose-ranging study, alongside placebo and liraglutide comparator groups.

The study was designed to characterize dose response, body-weight change, safety and tolerability rather than to establish that every finding applies outside the population and protocol studied.

Important: standalone cagrilintide data should be kept separate from results produced by cagrilintide plus semaglutide. They are different experimental interventions.

Combination research

Cagrilintide and Semaglutide Are Separate Research Compounds

One of the most important distinctions in current cagrilintide literature is between cagrilintide itself and the co-administration of cagrilintide with semaglutide.

Cagrilintide targets amylin-related signalling, whereas semaglutide is a GLP-1 receptor agonist. Combining the compounds therefore investigates two distinct receptor systems.

Feature	Cagrilintide	Semaglutide
Research class	Long-acting amylin analogue	GLP-1 receptor agonist
Primary signalling system	Amylin receptors	GLP-1 receptor
Peptide relationship	Engineered amylin analogue	Engineered GLP-1 analogue
Same molecule?	No — cagrilintide and semaglutide are distinct molecules.
Combination research	Co-administration has been studied in phase 2 and phase 3 clinical trials.

2025 phase 3 evidence

Cagrilintide Research in the REDEFINE 1 Trial

REDEFINE 1 was a large phase 3a randomized trial evaluating co-administered cagrilintide and semaglutide in adults with overweight or obesity who did not have diabetes.

Phase 3 — REDEFINE 1

Cagrilintide–Semaglutide Combination Research

A total of 3,417 participants underwent randomization. The trial included cagrilintide–semaglutide, semaglutide-alone, cagrilintide-alone and placebo groups.

At week 68, the estimated mean body-weight change was approximately −20.4% in the cagrilintide–semaglutide group compared with −3.0% in the placebo group under the reported treatment-policy estimand.

Gastrointestinal adverse events were common in the combination group and were reported as predominantly transient and mild-to-moderate in severity.

The −20.4% Result Is Not a Cagrilintide-Alone Result

This distinction is essential when discussing the REDEFINE 1 evidence.

The approximately −20.4% estimated mean change was reported for participants assigned to co-administered cagrilintide and semaglutide. It should not be presented as the effect of cagrilintide alone.

Type 2 diabetes research

Cagrilintide Research in the REDEFINE 2 Trial

REDEFINE 2 extended phase 3 combination research to adults with overweight or obesity and type 2 diabetes.

The double-blind randomized trial compared co-administered cagrilintide and semaglutide with placebo over 68 weeks, alongside lifestyle intervention.

As with REDEFINE 1, these results describe the combination intervention. They should not be used as evidence that cagrilintide alone produces the same outcomes.

Population matters: evidence generated in participants with type 2 diabetes should remain identified as evidence from that population rather than being generalized automatically to people without diabetes.

Evidence interpretation

Standalone vs Combination Cagrilintide Research

Research Program	Intervention	Population	Interpretation
Phase 2 dose-ranging trial	Cagrilintide alone	Adults with overweight or obesity without diabetes	Direct evidence concerning standalone cagrilintide
Phase 2 combination research	Cagrilintide + semaglutide	Studied metabolic populations	Evidence concerning co-administration
REDEFINE 1	Cagrilintide + semaglutide, with monotherapy comparator groups	Overweight or obesity without diabetes	Phase 3 combination evidence
REDEFINE 2	Cagrilintide + semaglutide	Overweight or obesity with type 2 diabetes	Phase 3 combination evidence in a distinct population

Peptide comparison

Cagrilintide Research Peptide vs Tirzepatide

Cagrilintide and tirzepatide belong to different peptide research classes.

Cagrilintide is an amylin analogue. Tirzepatide is a dual GIP and GLP-1 receptor agonist. Their clinical research may involve overlapping metabolic endpoints, but the underlying receptor pharmacology is different.

AMY

Cagrilintide Research

Long-acting amylin analogue investigated through amylin-related receptor signalling.

GIP+

Tirzepatide Research

Engineered peptide with dual GIP and GLP-1 receptor agonist activity.

For the dual incretin compound, see the Tirzepatide Research Peptide Overview.

Receptor comparison

Cagrilintide vs Retatrutide Research

Retatrutide differs even more substantially at the receptor level. Retatrutide is an engineered single peptide with activity at GIP, GLP-1 and glucagon receptors, whereas cagrilintide is designed around amylin-receptor biology.

Feature	Cagrilintide	Retatrutide
Research class	Long-acting amylin analogue	Triple-receptor agonist
Primary receptor system	Amylin-related receptors	GIPR, GLP-1R and GCGR
Molecular strategy	Engineered amylin analogue	Single engineered multi-receptor peptide
Same mechanism?	No — the compounds target substantially different receptor systems.

See the Retatrutide Research Peptide Overview and the Retatrutide vs Tirzepatide Research Comparison for related metabolic-receptor research.

Safety evidence

Safety and Tolerability in Cagrilintide Research

Safety findings must be tied to the specific intervention and trial in which they were observed.

In REDEFINE 1, gastrointestinal adverse events were common with the cagrilintide–semaglutide combination. Reported events included nausea, vomiting, diarrhea, constipation and abdominal pain, and most were described as transient and mild-to-moderate.

That safety profile represents a studied combination in a defined clinical-trial population. It should not be treated as a universal safety characterization for unapproved research materials or different experimental conditions.

Research-use distinction: published pharmaceutical clinical-trial results do not establish the safety, suitability or equivalence of independently supplied laboratory research materials.

Research interpretation

How to Evaluate Cagrilintide Research Peptide Evidence

The growing clinical literature makes cagrilintide an important research subject, but several distinctions are necessary when interpreting the evidence.

✓ Separate cagrilintide-alone studies from combination studies.

✓ Do not attribute CagriSema results to cagrilintide alone.

✓ Distinguish amylin signalling from GLP-1 signalling.

✓ Identify the population studied in each trial.

✓ Separate phase 2 evidence from phase 3 evidence.

✓ Keep endpoints tied to the duration and protocol studied.

✓ Distinguish published pharmaceutical trial material from laboratory research material.

✓ Avoid translating trial findings into personal-use guidance.

Analytical quality

Testing a Cagrilintide Research Peptide Batch

Published clinical trials establish information about the pharmaceutical materials used within those trials. They do not establish the identity, purity or measured content of an unrelated research batch.

Laboratory researchers should therefore evaluate the analytical documentation associated with the specific material and batch being studied.

✓ Match documentation to the batch identifier.

✓ Review identity testing where reported.

✓ Review chromatographic purity where reported.

✓ Review measured peptide content where reported.

✓ Confirm which analytical methods were used.

✓ Distinguish identity, purity and measured content.

✓ Review additional tests only when documented for that batch.

✓ Do not transfer results from another batch.

See Peptora's Testing & COAs, Testing Standards and Peptide Purity & Certificates of Analysis Explained.

Research network

Continue Exploring Cagrilintide Research Peptide Topics

Cagrilintide adds the amylin pathway to Peptora's growing research library and provides an important contrast with incretin and multi-receptor peptide research.

Cagrilintide and Related Research Resources

Compare peptide classes, receptor systems and analytical evidence before transferring findings between different research compounds.

Tirzepatide Research Peptide Overview → Retatrutide Research Peptide Overview → Retatrutide vs Tirzepatide Comparison → Commonly Studied Research Peptides → What Are Research Peptides? → Understanding Peptide Stability → Testing & COAs → Complete Research Library →

Cagrilintide FAQ

Cagrilintide Research Peptide: Frequently Asked Questions

Common research questions about cagrilintide, amylin biology, receptor signalling and published clinical research.

What is the cagrilintide research peptide?

Cagrilintide is an engineered, lipidated, long-acting analogue of the pancreatic peptide hormone amylin. It has been investigated in research involving amylin-receptor signalling, satiety, food intake and metabolic biology.

Is cagrilintide a GLP-1 receptor agonist?

No. Cagrilintide is an amylin analogue. Its primary research framework involves amylin-related receptors rather than the GLP-1 receptor.

What is natural amylin?

Amylin, also called islet amyloid polypeptide, is a peptide hormone produced by pancreatic beta cells and co-secreted with insulin. It participates in physiological signalling involving satiety and food intake.

Has cagrilintide been studied by itself?

Yes. A randomized phase 2 dose-ranging trial evaluated once-weekly cagrilintide as a standalone intervention in adults with overweight or obesity without diabetes.

What is cagrilintide with semaglutide?

Clinical research has evaluated co-administration of the amylin analogue cagrilintide with the GLP-1 receptor agonist semaglutide. The compounds remain separate molecules targeting different receptor systems.

What did REDEFINE 1 study?

REDEFINE 1 was a phase 3a trial involving adults with overweight or obesity without diabetes. It evaluated co-administered cagrilintide and semaglutide and included semaglutide-alone, cagrilintide-alone and placebo comparator groups.

Did cagrilintide alone produce the approximately 20% mean weight change reported in REDEFINE 1?

No. The approximately 20.4% estimated mean body-weight reduction at week 68 was reported for the cagrilintide–semaglutide combination group, not cagrilintide alone.

How should a cagrilintide research batch be evaluated?

Researchers should review batch-specific analytical documentation and distinguish identity, purity, measured content and any additional testing actually reported for that material. Clinical-trial data do not establish the analytical characteristics of an unrelated research batch.

Research use only

Cagrilintide Research Peptide for Controlled Laboratory Research

This page provides educational information about cagrilintide, amylin biology, receptor signalling and published preclinical and clinical research. Clinical-trial results are included to describe the scientific literature and do not provide personal-use guidance.

Peptora Peptide Labs research materials are intended solely for controlled non-clinical laboratory research. They are not intended for human or veterinary consumption, compounding or clinical use. Nothing on this page provides medical advice, dosing or administration guidance or represents that cagrilintide diagnoses, treats, cures or prevents disease.